In Vivo Testing, Biodistribution, and Efficacy of <i>JX-795</i>

<div><p>(A) mIFN-β levels were determined by ELISA in the serum, and the tumors of animals (BALB/c bearing subcutaneous JC tumors) treated with (1 × 10⁸ PFU) <i>JX-795</i> (ΔB18RΔTK-IFNb), ΔB18RΔTK virus, or PBS 72 h earlier (<i>n</i> = 3/group).</p> <p>(B) Biodistribution of viral gene expression (as determined by bioluminescence imaging of mice treated with viruses expressing luciferase). Mice (BALB/c) bearing subcutaneous JC tumors (arrows) were treated with a single tail vein injection of 1 × 10⁸ PFU of viruses, <i>TK</i>-deleted (ΔTK-luc; squares), ΔB18RΔTK-luc (triangles), or ΔB18RΔTK-luc-IFNb (<i>JX-795</i>; circles), and imaging performed after luciferin addition. Representative images were taken at 72 h post-treatment. Bioluminescence was quantified over the tumor and the torso of the treated animals (<i>n</i> = 3/group) at times post-treatment (middle and bottom right-hand panels; symbols are for both graphs).</p> <p>(C) Survival curves of BALB/c mice bearing subcutaneous JC tumors and treated with a single tail vein injection of 1 × 10⁸ PFU of ΔB18RΔTK virus (diamonds), ΔB18RΔTK-IFNb (<i>JX-795</i>; triangles) or PBS (squares) (<i>p</i> = 0.028 for ΔB18RΔTK relative to ΔB18RΔTK-IFNb).</p>